B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib

The coexistence of two diseases chronic myeloid leukemia (CML) and B-cell chronic lymphocytic leukemia (B-CLL) is a rare phenomenon. Both neoplastic disorders have several common epidemiological denominators (they occur more often in men over 50 years of age) but different origin and long term progn...

Full description

Saved in:

Bibliographic Details
Main Authors:	Krzysztof Lewandowski, Michał Gniot, Maria Lewandowska, Anna Wache, Błażej Ratajczak, Anna Czyż, Małgorzata Jarmuż-Szymczak, Mieczysław Komarnicki
Format:	Article
Language:	English
Published:	Wiley 2016-01-01
Series:	Case Reports in Medicine
Online Access:	http://dx.doi.org/10.1155/2016/9806515
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chronic myeloid leukemia — before and after imatinib (First part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (part II)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Chronic myeloid leukemia in the Imatinib era - Compilation of Indian data from 22 centers involving 8115 patients
by: Purvish Parikh, et al.
Published: (2013-01-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
by: Kibum Kim, et al.
Published: (2019-01-01)

Bilateral mandibular osteonecrosis associated with imatinib monotherapy for a patient with chronic myeloid leukemia
by: Yasuharu Yajima, et al.
Published: (2025-04-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

EFFECT OF FREQUENT GENERIC IMATINIB SWITCHING ON TREATMENT RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Murat Çınarsoy, et al.
Published: (2024-12-01)

Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development
by: Irina Badralexi, et al.
Published: (2024-12-01)

Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
by: Fatemeh Ensafi Talemi, et al.
Published: (2025-01-01)

Profile of pediatric chronic myeloid leukemia in the era of imatinib: A study from South India
by: Catherene Bernard, et al.
Published: (2019-01-01)

Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
by: Michiels S, et al.
Published: (2024-09-01)

Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia chronic phase on frontline imatinib
by: Ranga Raman Ganta, et al.
Published: (2017-01-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

A newborn with congenital mixed phenotype acute leukemia with complex translocation t(10;11)(p12;q23) with KMT2A/MLLT10 rearranged – a report of an extremely rare case
by: Dawid Szpecht, et al.
Published: (2018-10-01)

Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country
by: Lydie Ocini Ngolet, et al.
Published: (2016-01-01)

Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia
by: Feng Wang, et al.
Published: (2025-01-01)

miR-155 and miR-223 as markers of biological and clinical features of chronic lymphocytic leukemia
by: M. L. Perepechaeva, et al.
Published: (2024-03-01)

METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
by: O. V. Smirnova, et al.
Published: (2014-07-01)

Chronic myeloid leukemia in India
by: John M Goldman
Published: (2013-01-01)

Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib
by: Ikhlas Khammas, et al.
Published: (2025-06-01)

New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib
by: Dinara Salimova, et al.
Published: (2025-04-01)

Long-Term Safety and Efficacy of Imatinib in Chronic Myeloid Leukemia: Real-World Evidence from a Single-Center Study
by: İsmail Can Kendir, et al.
Published: (2025-06-01)

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming
by: Lan Yang, et al.
Published: (2025-07-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Effect of N-acetyl-L-cysteine on human chronic myeloid leukemia cells KCL22 treated with mitomycin C
by: Jin Kyu Ki, et al.
Published: (2014-03-01)

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
by: Hongpeng Duan, et al.
Published: (2024-12-01)

Retinal infiltration by chronic myeloid leukemia
by: Maïlys Charmasson, et al.
Published: (2025-03-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: AnnaMaria Nosari
Published: (2012-11-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)